Indian Pharmacopoeia Commission regularly monitoring adverse events of weight-loss drugs ...
FormBlends' platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 billion globally in 2025 and is projected to grow to $260.25 billion by ...
FormBlends' platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 ...
Avacopan shows a favorable safety profile in ANCA-associated vasculitis in real-world settings, with hepatobiliary events as ...
As the use of these drugs expands, so does research on how they affect a person’s well-being beyond their metabolism, ...
As estimates released by Planned Parenthood s former research arm show that abortion in the United States continues to rise ...
Detailed price information for Red Light Holland Corp (TRIP-CN) from The Globe and Mail including charting and trades.
An update on CAR-T therapies for MM and B-cell NHL presented at the 2026 ONA Summit highlighted the integral role of oncology nurses in ensuring patients achieve optimal outcomes.
A study, published in Nature, investigated drugs such as semaglutide and tirzepatide, which have gained global attention for ...
A large 23andMe-based GWAS found that common variants in GLP1R and GIPR help explain why some people lose more weight or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results